Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Phase 1 cleared for Celyad
October 2016
SHARING OPTIONS:

MONT-SAINT-GUIBERT, Belgium—Cell therapy company Celyad recently completed the 21-day safety follow-up of the last patient enrolled at the fourth dose level in its Phase 1 clinical trial. The trial focused on assessing the safety and feasibility of its NKR-2 T cell therapy in patients with acute myeloid leukemia and multiple myeloma, and no safety issues or toxicities were reported.
 
Dr. Christian Homsy, CEO of Celyad, noted in a press release that “We are pleased that no adverse safety signal has been reported. Based on the successful completion of the fourth cohort, we are looking forward to starting the global Phase 1/2a multiple dose trial, in the U.S. and EU, of our NKR-2 autologous therapy in the fourth quarter of this year.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.